Composition and methods of genome editing of b-cells
AssigneeDana-Farber Cancer Institute, Inc.
InventorsMicheal Goldberg, Vera Greiner
Life of this patent
Estimating the term…
Abstract
The present invention provides methods compositions and methods of preparing autologous (or allogeneic) B cells that secrete a monoclonal of interest useful in immunotherapy or B cells with an altered function.
Claims17
1-52. (canceled)
A primary human B cell that produces a heterologous therapeutic antibody, comprising the primary human B cell with variable regions of light and heavy chains of an endogenous B cell receptor substituted with variable regions of heterologous light and heavy chains of the heterologous therapeutic antibody.
A population of modified primary human B cells, comprising a population of primary B cells that has been gene-edited to substitute variable regions of the light and heavy chains of an endogenous B cell receptor with variable regions of light and heavy chains of a heterologous antibody.
Dependencies are inferred from the claim text.